Clinical Trial Search

Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88

Primary: Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population — 1.823; 2.978 Pearl Index

Primary: Matsuda Index- Whole Body Insulin Sensitivity Index — -1.02; -0.10; -1.45 units on a scale — p=0.27

Primary: Ovulation Suppression in Three Treatment Groups Over 3 Cycles — 36.5; 20.7; 11.5; 36.9 %of cycles with possible ovulation

Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705

Primary: Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population, — 2.554 Pregnancy Rate

Primary: The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 16 to 35 Years, Inclusive, at the Time of…

Primary: Hot Flashes — 10.3; 7.944 scores on a scale

Primary: Number of Pregnancies (Evaluable Cycles) — 2.9 Pearl Index

Primary: Change in Biochemical Hyperandrogenism From Baseline to 1 Month Post Yasmin Initiation — -15.38; -8.54 ng/dl

Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants

Primary: Changes in Insulin-like Growth Factor-1 (IGF-1), IGF Binding Proteins (IGFBP-1, IGFBP-3), and Acid Labile Subunit (ALS) — 220.6; 228.7; 197.1; 221.4 ng/mL

Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants

Primary: The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of…

Primary: SERUM PROGSTERONE CONCENTRATION — 0.74; 0.45 ng/mL — p=<0.05

Primary: Pearl Index, 18-35 Years, MITT Population — 1.903 Pearl Index

Primary: Change in Serum EE2 Levels Over 12 Weeks of Continuous Contraceptive Patch Use — 12.5; 14.3; 10.9; 42.9 pg/ml

Primary: Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol — 1275; 1240; 21.9; 14.8 ng/L

Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120

Primary: LH Pulse Frequency — 1.31; 0.91; 1.33; 1.19 pulses/hour

Primary: Serum Concentration of Prothrombin Fragments 1 + 2 — 0.18; 0.19; 0.31; 0.42 nmol/L — p=0.0849

Primary: Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy — 2.44; 2.42; 1.77…

Primary: Cessation of Vaginal Bleeding — 37.5; 87.5 percentage of participants

Primary: Number of Live Births — 3; 1 live births

Primary: Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) — 0.467; 1.017; 0.571; 1.261 Pregnancies per 100 woman years

Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml

Primary: Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) — 1.754; 3.005; 1.963; 3.092 Pregnancies per 100 woman years

Primary: Effect on Ovarian Function as Determined by the Number of Participants With an Occurrence of Ovulation — 0; 0; 0; 0 Participants

Primary: Pregnancy — 5.41; 6.67; 6.43 Pearl Index

Primary: Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35) — 22.4 pregnancies per 100 woman years